Vancomycin and Rifaximin Combination Therapy for Diarrhoea Predominant Irritable Bowel Syndrome: An Observational Study

Authors: P. Murphy, D. Vasic, A. W. Gunaratne, T. Tugonon, M. Ison, C. Pagonis, E. T. Sitchon, A. Le Busque, T. J. Borody

Abstract:

Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by an alteration in bowel movements. There are three different types of IBS: diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C) and IBS with mixed bowel habit (IBS-M). Antimicrobials are increasingly being used as treatment for all types of IBS. Due to this increased use and subsequent success, the gut microbiome as a factor in the etiology of IBS is becoming more apparent. Accepted standard treatment has focused on IBS-C and involves either vancomycin or rifaximin. Here, we report on a cohort of 18 patients treated with both vancomycin and rifaximin for IBS-D. These patients’ records were reviewed retrospectively. In this cohort, patients were aged between 24-74 years (mean 44 years) and nine were female. At baseline all patients had diarrhea, four with mucus and one with blood. Other reported symptoms include abdominal pain (n = 11) bloating (n = 9), flatulence (n = 7), fatigue (n = 4) and nausea (n = 3). Patient’s treatments were personalized according to their symptom severity and tolerability and were treated with a combination of rifaximin (500-3000 mg/d) and vancomycin (500 mg-1500 mg/d) for an ongoing period. Follow-ups were conducted between 2-32 weeks. Of all patients, 89% reported improvement of at least 1 symptom, one reported no change and one patient’s symptoms got worse. The success of this combination treatment could be due to the different mechanisms of action undertaken by each medication. Vancomycin works by inhibiting the cell wall of the bacteria and rifaximin by inhibiting protein synthesis. This success in treatment validates the idea that IBS-D may be driven by a bacterial infection of the gastrointestinal microbiome. As IBS-D presents similarly to Clostridium difficile and symptom improvement can occur with the same treatment as Clostridium difficile of rifaximin and vancomycin, there is reason to suggest that the infectious agent could be an unidentified strain of Clostridium. Although these results offer some validity to the theory, more research is required.

Keywords: Clostridium difficile infection, diarrhea predominant irritable bowel syndrome, microbiome, vancomycin/rifaximin combination.

References:

[1] C. Canavan, J. West, and T. Card, “The epidemiology of irritable bowel syndrome,” Clin. Epidemiol., vol. 6, no. 1, p. 71, Feb. 2014, doi: 10.2147/CLEP.S40245.
[2] R. J. Basseri, S. Weitsman, G. M. Barlow, and M. Pimentel, “Antibiotics for the Treatment of Irritable Bowel Syndrome,” Gastroenterol. Hepatol. (N. Y)., vol. 7, no. 7, p. 455, Jul. 2011, Accessed: Jul. 27, 2022. (Online). Available: /pmc/articles/PMC3264894/
[3] L. Chang, S. Sultan, A. Lembo, G. N. Verne, W. Smalley, and J. J. Heidelbaugh, “AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation,” Gastroenterology, vol. 163, no. 1, pp. 118–136, Jul. 2022, doi: 10.1053/j.gastro.2022.04.016.
[4] C. C. Herndon, Y. P. Wang, and C. L. Lu, “Targeting the gut microbiota for the treatment of irritable bowel syndrome,” Kaohsiung J. Med. Sci., vol. 36, no. 3, pp. 160–170, Mar. 2020, doi: 10.1002/KJM2.12154.
[5] Z. Mamieva et al., “Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?,” World J. Gastroenterol., vol. 28, no. 12, pp. 1204–1219, Mar. 2022, doi: 10.3748/WJG.V28.I12.1204.
[6] M. Pimentel, S. Park, J. Mirocha, S. V. Kane, and Y. Kong, “The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial,” Ann. Intern. Med., vol. 145, no. 8, pp. 557–563, Oct. 2006, doi: 10.7326/0003-4819-145-8-200610170-00004.
[7] A. Sharara, E. Aoun, H. Abdul-Baki, R. Mounzer, S. Sidani, and I. ElHajj, “A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence.,” Am. J. Gastroenterol., vol. 101, no. 2, pp. 326–333, 2006.
[8] T. Fujikawa et al., “Post-Infectious Irritable Bowel Syndrome with Functional Diarrhea Following C. difficile Infections: Case Studies of Responses Using Serum-Derived Bovine Immunoglobulin,” J. Gastroenterol. Hepatol. Res., vol. 4, no. 4, pp. 1577–1581, Apr. 2015, doi: 10.6051/.
[9] A. F. CELIK, J. TOMLIN, and N. W. READ, “The effect of oral vancomycin on chronic idiopathic constipation,” Aliment. Pharmacol. Ther., vol. 9, no. 1, pp. 63–68, Feb. 1995, doi: 10.1111/J.1365-2036.1995.TB00353.X.
[10] N. Roshan, A. Clancy, and T. Borody, “S3151 Personalised Combination Antibiotic Therapy Is Effective for Constipation,” Am. J. Gastroenterol., vol. 115, no. 1, pp. S1656–S1656, Oct. 2020, doi: 10.14309/01.AJG.0000714652.34455.04.
[11] J. K. Beatty, A. Bhargava, and A. G. Buret, “Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection,” World J. Gastroenterol., vol. 20, no. 14, pp. 3976–3985, 2014, doi: 10.3748/WJG.V20.I14.3976.
[12] N. Lazaridis and G. Germanidis, “Current insights into the innate immune system dysfunction in irritable bowel syndrome,” Ann Gastroenterol, vol. 31, no. 1, pp. 1–17, 2018, doi: 10.20524/aog.2018.0229.
[13] J. J. Martin-Viñas and E. M. M. Quigley, “Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators,” J. Dig. Dis., vol. 17, no. 9, pp. 572–581, Sep. 2016, doi: 10.1111/1751-2980.12379.
[14] S. M. P. Bennet et al., “Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome,” Am. J. Gastroenterol., vol. 111, no. 8, pp. 1165–1176, Aug. 2016, doi: 10.1038/AJG.2016.223.
[15] P. C. Appelbaum, “Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA),” Int. J. Antimicrob. Agents, vol. 30, no. 5, pp. 398–408, Nov. 2007, doi: 10.1016/J.IJANTIMICAG.2007.07.011.
[16] G. R. Lichtenstein, “Rifaximin: Recent Advances in Gastroenterology and Hepatology,” Gastroenterol. Hepatol. (N. Y)., vol. 3, no. 6, p. 474, Jun. 2007, Accessed: Aug. 15, 2022. (Online). Available: /pmc/articles/PMC3099332/
[17] L. Gerard, K. W. Garey, and H. L. DuPont, “Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections,” http://dx.doi.org/10.1586/14787210.3.2.201, vol. 3, no. 2, pp. 201–211, Apr. 2014, doi: 10.1586/14787210.3.2.201.
[18] D. W. Hecht, M. A. Galang, S. P. Sambol, J. R. Osmolski, S. Johnson, and D. N. Gerding, “In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004,” Antimicrob. Agents Chemother., vol. 51, no. 8, p. 2716, Aug. 2007, doi: 10.1128/AAC.01623-06.
[19] J. Pepin, “Vancomycin for the Treatment of Clostridium difficile Infection: For Whom Is This Expensive Bullet Really Magic?,” Clin. Infect. Dis., vol. 46, pp. 1493–1501, 2008, doi: 10.1086/587656.
[20] L. C. Mcdonald et al., “Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA),” Clin. Infect. Dis. Clin. Pract. Guidel. Clostridium difficile Infect. • CID, vol. 2018, p. 1, doi: 10.1093/cid/cix1085.